“To name things wrongly is to add to the misfortune of the world”, (e-Letter in response to: For better drugs, diversify clinical trials.

• publication
• 14-04-2021

Grenet G, Gombault C, Duret L, Sanchez-Mazas A, Gueyffier F, Segurel L, Lega J-C. Science 05 Feb 2021: Vol. 371, Issue 6529, pp. 570-571 DOI: 10.1126/science.abe2565

We read with great interest the perspective by Bumpus (1), who describes the issue of overrepresenting individuals of European ancestry in pharmacological trials. The author highlights the inequities this can translate into and the efforts needed in reporting ethnicity in trials, in line with the STROPS guideline (2). However, this raises several concerns.

see on external website